Retro Biosciences

It's pretty cool, right? Then there's Sam Altman, the chat GBT guy, the face of the AI boom.

Altman puts $180 million of his own money into a longevity startup called Retro Biosciences.

And here's the twist that only happens in 2026.

Retro hooked up with Altman's other company, OpenAI, and they're using artificial intelligence to design the proteins that turn old cells yum.

Pretty, pretty, pretty interesting.

And then also, um, you know, there's a company called Retro Biosciences.

Uh, have you been-

Ooh

Oh, yeah.

No.

Retro Biosciences is a OpenAI, Sam Altman-funded company, um, out of San Francisco that are modifying the Yamanaka factors, um, using AI and creating thousands of different versions-

Mm

Brian Armstrong, the head of the cryptocurrency company Coinbase, helped start a firm called New Limit in 2022.

Diseases, then longevity, its webpage announces, the same year Sam Altman, the CEO of OpenAI, invested in a company with a similar anti-aging mission named Retro Biosciences.

Also in 2022 came the behemoth of the industry, Alto's Labs.

headquartered in the San Francisco Bay Area.

its web page announces.

The same year, Sam Altman, the CEO of OpenAI, invested in a company with a similar anti-aging mission named Retro Biosciences.

Also in 2022 came the behemoth of the industry, Alto Labs, headquartered in the San Francisco Bay Area.

It started with $3 billion in investment money, part of which reportedly came from Jeff Bezos.

There's a third example worth naming because it closes the loop between faster drugs and aging specifically.

Retro Biosciences, backed by OpenAI's Sal Maltman, which reported a $180 million in initial funding, is using AI models to search for combinations of cellular reprogramming factors, proteins that can nudge an old cell back to a younger state, faster than a human researcher could screen them by hand.

That's the same reprogramming technology we'll come back to in a few minutes.

And the same caveat applies there too.

Diseases, then longevity, its webpage announces.

The same year, Sam Altman, the CEO of OpenAI, invested in a company with a similar anti-aging mission named Retro Biosciences.

Also in 2022 came the behemoth of the industry, Alto Labs, headquartered in the San Francisco Bay Area.

It started with $3 billion in investment money, part of which reportedly came from Jeff Bezos.

Diseases, then longevity, its web page announces.

The same year, Sam Altman, the CEO of OpenAI, invested in a company with a similar anti-aging mission named Retro Biosciences.

Also in twenty twenty-two came the behemoth of the industry, Alto Labs, headquartered in the San Francisco Bay Area.

It started with three billion dollars in investment money, part of which reportedly came from Jeff Bezos.